our goal is to create a high-level architecture for the system that will analyze real-life drug performance in the market using Electronic Medical Record (EMR) data from providers. You will contract with providers to pull in their data from any EMR regardless of the vendor, bring it into a batch, process, normalize, and make available to your Data Scientists internally for evaluation. More specifically, you are looking for certain patterns indicative of an issue such as side effects, collecting information about details and quantity of those side effects, and reporting on a certain set of attributes selected by analyst to address the research question about a drug and its real-life performance. You will use a specific drug, called Darvocet, (that was taken off the market for a specific reason in the past), as your pilot for evaluating whether the system works and how the system works. Assume a few pilot provider sites may participate in your study. They will gain the first adopter benefits and related discounts for a finished product, should you be successful. Your general steps are as follows. Your detailed steps are completely open to your interpretation, based on your research, attendance of a lecture related to Unit 6, and the readings.
1. Find and research Darvocet. Pay special attention to its purpose, intended clinical goals and patients, side effects, and reasons it was taken off the market.
2. Determine how you would structure your system to (a) extract relevant clinical data from provider EMRs, (b) process data at the arrival point when it is loaded in bulk into from various EMR sources into your system, (c) store the data at the arrival point, (d) analyze data inside your database, and (e) supply relevant reports to your life sciences clients. Describe your logic
3. In conclusion, explain how and why your system would work, represent an innovation, and justify value for your clients. Do remember that you need to return value to your health care providers who signed up as early testers, in addition to your “primary” clients in life sciences. The question you will strive to answer is, if you had this pilot in your hands before Darvocet was pulled off the market, how could you either prevent it or help your client improve the drug by the ways of supplying early trouble indicators and feeding into the Version 2 development process?